



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		Application Number	10/611,598
		Filing Date	June 30, 2003
		First Named Inventor	Johannes B.M.M. van Bree
		Art Unit	unassigned
		Examiner Name	unassigned
Total Number of Pages in This Submission		Attorney Docket Number	16994G-012730US

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Ausenhus	Reg. No. 42,271
Signature		
Date	11-20-03	

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Nicole M. Wartell		
Signature		Date	11-20-03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 16994G-012730US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On November 20, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Nicole M. Wartell  
Nicole M. Wartell

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Johannes B.M.M. van Bree

Application No.: 10/611,598

Filed: June 30, 2003

For: TREATMENT OF POMPE'S  
DISEASE

Examiner: *unassigned*

Art Unit: *unassigned*

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. This application is a continuation of and relies upon U.S. Patent Application No. 09/454,711 for an earlier effective filing date under 35 U.S.C. §120. In accordance with 37 CFR §1.98(d), all of the references have been previously submitted to or cited by the Office in the parent application, and are therefore not enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhuis  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
60085041 v1




<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/611,598	
			Filing Date	June 30, 2003	
			First Named Inventor	van Bree, Johannes B.M.M.	
			Art Unit	unassigned	
			Examiner Name	unassigned	
Sheet	1	of	3	Attorney Docket Number	16994G-012730US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-5,356,804	10-18-1994	Desnick et al.	
	A2	US-5,565,362	10-15-1996	Rosen	
	A3	US-6,118,045	09-12-2000	Reuser et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	PCT	WO 93/25567	A	12-23-1993			<input type="checkbox"/>
	B2	PCT	WO 97/05571	A2	02-20-1997			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60085041 v1



Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/611,598		
		Filing Date	June 30, 2003		
		First Named Inventor	van Bree, Johannes B.M.M.		
		Art Unit	unassigned		
		Examiner Name	unassigned		
Sheet	2	of	3	Attorney Docket Number	16994G-012730US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Barnes, Alison K. & Wynn, Colin H. "Homology of Lysosomal Enzymes and Related Proteins: Prediction of Posttranslational Modification Site Including Phosphorylation of Mannose and Potential Epitopic and Substrate Binding Sites in the $\alpha$ - and $\beta$ -Subunits of Hexosaminidases, $\alpha$ -Glucosidase, and Rabbit and Human Isomaltase" <i>Proteins: Structure, Function, and Genetics</i> , 1988, Vol.4, pp.182-189.	
	C2	Belen'kii, D. M. et al. "Purification and Properties of Acid $\alpha$ -Glucosidase ( $\gamma$ -Amylase) from Human Liver." Translated from: <i>Biokhimiya</i> , Sept-Oct 1975, 40 (5) pp. 927-933.	
	C3	Bijvoet, Agnes G. A. et al., "Expression of cDNA-Encoded Human Acid $\alpha$ -Glucosidase in milk of Transgenic Mice," <i>Biochimica and Biophysica Acta</i> , Volume 1308, 1996, pp. 93-96.	
	C4	Bresciani, Roberto et al. "Lysosomal acid phosphatase is not involved in the dephosphorylation of mannose 6-phosphate containing lysosomal proteins." <i>Eur. J. of Cell Biol.</i> June 1992, Vol. 58, No. 1, pages 57-61.	
	C5	de Barsey et al. "Enzyme Replacement in Pompe Disease: an Attempt with Purified Human Acid Alpha Glucosidase", <i>Birth Defects Original Article Series</i> , 9 (2) pp. 184-190 March 1973.	
	C6	Hoefsloot, Lies H. et al., "Expression and Routeing of Human Lysosomal $\alpha$ -Glucosidase in Transiently Transfected Mammalian Cells," <i>Biochemical Journal</i> , 1990, Volume 272, pp. 485-492.	
	C7	Houdebine, Louis-Marie "Production of pharmaceutical proteins from transgenic animals." <i>J. of Biotech.</i> , 1994, Vol. 34, pages 269-287, Elsevier Publishing.	
	C8	Kichuchi et al., "Clinical and Metabolic Correction of Pompe Disease by Enzyme Therapy in Acid Maltase-Deficient Quail", <i>J. Clin. Invest.</i> , 101 (4) pp. 827-833, February 1998.	
	C9	Minamiura, Noshi et al. "Identity of $\alpha$ -Glucosidase of Human Kidney with Urine F-1 $\alpha$ -Glucosidase." <i>J. Biochemistry</i> , 1982, Vol. 91, pages 809-816.	
	C10	Obara, Yoshiaki et al. "Mutual relationship between milk components and lysosome enzymatic activity in abnormal milk." <i>Japanese Journal of Veterinary Science</i> , 1983, Vol. 45, No. 2, pages 203-208.	
	C11	Oberkotter, Linda V. et al. "N-acetyl- $\beta$ -hexosaminidase activity in human breast milk." <i>International Journal of Biochemistry</i> , 1982, Vol. 14, No. 2, pages 151-154.	
	C12	Platenburg Gerard J. et al., "Expression of Human Lactoferrin in Milk of Transgenic Mice," <i>Transgenic Research</i> , 1994, Volume 3, pp. 99-108.	
	C13	Rocheftort, Henri et al., "The Estrogen-Regulated 52K-Cathepsin-D in Breast Cancer: From Biology to Clinical Applications," <i>Nuclear Medicine and Biology</i> , 1987, Volume 14, No. 4, pp. 377-384.	
	C14	Van der Ploeg, A. T. et al., "Intravenous Administration of Phosphorylated Acid $\alpha$ -Glucosidase Leads to Uptake of Enzyme in Heart and Skeletal Muscle of Mice," <i>The Journal of Clinical Investigation</i> , February 1991, Volume 87, No. 2, pp. 513-518.	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/611,598
				Filing Date	June 30, 2003
				First Named Inventor	van Bree, Johannes B.M.M.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	3	of	3	Attorney Docket Number	16994G-012730US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C15	Van Hove et al., Purification of Recombinant Human Precursor Acid Alpha Glucosidase, Biochemistry and Molecular Biology International, 43 (3) pp. 613-623, October 1997.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.